Nutra Pharma Corp (NPHC) Cost of Revenue (2010 - 2026)

Nutra Pharma has disclosed Cost of Revenue across 17 years of filings, most recently posting $25297.0 for Q2 2026.

• In Q2 2026, Cost of Revenue fell 56.92% year-over-year to $25297.0; the TTM figure through Jun 2026 stood at $154637.0 (up 3.99% YoY), while the FY2025 annual figure was $183679.0, up 116.53% from the prior year.
• Cost of Revenue came in at $25297.0 for Q2 2026 at Nutra Pharma, down from $29239.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $80252.0 in Q2 2023 to a low of $14406.0 in Q1 2022.
• Average Cost of Revenue over 5 years is $38044.9, with a median of $31683.5 recorded in 2025.
• Year-over-year, Cost of Revenue surged 575.07% in 2022 and sank 76.79% in 2024.
• Over 5 years, Cost of Revenue stood at $46588.0 in 2022, then sank by 55.99% to $20503.0 in 2023, then slipped by 2.74% to $19942.0 in 2024, then jumped by 230.82% to $65973.0 in 2025, then tumbled by 61.66% to $25297.0 in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $25297.0 in Q2 2026, $29239.0 in Q1 2026, and $65973.0 in Q4 2025.